Campus alert status is yellow: For the latest campus alert status, news and resources, visit

Search Close Search
Search Close Search
Page Menu

Glibenclamide for Large Hemispheric Infarction Analyzing mRS and Mortality


Site Primary Investigator (UMASS): Raphael A. Carandang, MD.

Design: A randomized, multi-center, placebo-controlled, double-blinded trial.

Funded by: Biogen Inc.


Primary Objective:

-To determine if BIIB093 improves functional outcome in comparison to placebo in patients with large hemispheric ischemic stroke.

Secondary Objectives:

-To determine BIIB093’s safety profile, improvement in survival, and reduction in midline shift in comparison to placebo use.

Outcome measures:  Improvement of mRS at day 90.

Anticipated study duration: 4-5 years

Anticipated patient enrollment: Total of 600 subjects and up to 80 subjects with age >70 years and up to 85 years (inclusive). Link: 


AE = adverse event; ASPECTS = Alberta Stroke Program Early CT Score; BI = Barthel index; CT = computerized tomography; CTP = computed tomography perfusion; ECG =electrocardiogram; EQ-5D = EuroQol; MRI = magnetic resonance imaging; mRS = modified Rankin scale; NIHSS = National Institues of Health Stroke Scale; rtPA = recombinant tissue plasminogen activator; SAE = serious adverse event; SIS = stroke impact scale; SOC =standard of care; TOAST = trial of Org 10172 in acute stroke treatment


*Cirara is intravenoues Glyburide

IND number: 128581; EnduraCT number: 2016-001932-36